MIAT: An important long non-coding RNA regulating cardiovascular and cerebrovascular diseases
-
By
-
Yuxin Pan
-
Wusheng Yu
-
Yantao Han
-
Yingchun Shao
-
July 13, 2026
Clinical Scorecard: MIAT: A Key Long Non-Coding RNA Influencing Cardiovascular and Cerebrovascular Disorders
At a Glance
| Category | Detail |
|---|
| Condition | Cardiovascular and cerebrovascular diseases |
| Key Mechanisms | Regulatory functions of long non-coding RNA MIAT in gene expression and cellular responses. |
| Target Population | Individuals at risk for myocardial infarction and cerebrovascular disorders. |
| Care Setting | Clinical research and translational applications. |
Key Highlights
- MIAT is implicated in various diseases beyond myocardial infarction, including ischemic stroke and cancer.
- Aberrant expression of MIAT may serve as a promising therapeutic candidate.
- The review integrates both cardiovascular and cerebrovascular pathologies related to MIAT.
- MIAT exhibits dynamic subcellular localization affecting its function.
- Current challenges and future directions for clinical application of MIAT are discussed.
Guideline-Based Recommendations
Diagnosis
- Consider MIAT as a potential biomarker for cardiovascular and cerebrovascular diseases.
Management
- Further research is needed to explore MIAT as a therapeutic target.
Monitoring & Follow-up
- Monitor MIAT expression levels in patients with cardiovascular and cerebrovascular disorders.
Risks
- Genetic variations in MIAT may be associated with increased risk of myocardial infarction.
Patient & Prescribing Data
Patients with cardiovascular and cerebrovascular diseases.
No clinical trials targeting MIAT have been registered to date.
Clinical Best Practices
- Integrate findings on MIAT into clinical research for potential therapeutic applications.
- Utilize MIAT expression levels in risk assessment for cardiovascular events.
Related Resources & Content
